Hong Kong Finance

Aug 25 2017

Alzheimer s Association – Treatment Horizon #alzheimers #drugs, #dementia #drugs, #alzheimers #treatment, #dementia #treatment, #beta-amyloid, #alzheimers #trials, #alzheimers #studies, #dementia #studies, #memory #studies, #brain #studies, #brain #research, #alzheimers #research, #dementia #research


#

Treatment Horizon

A worldwide quest is under way to find new treatments to stop, slow or even prevent Alzheimer’s. Because new drugs take years to produce from concept to market—and because drugs that seem promising in early-stage studies may not work as hoped in large-scale trials—it is critical that Alzheimer’s and related dementias research continue to accelerate. To ensure that the effort to find better treatments receives the focus it deserves, the Alzheimer’s Association funds researchers looking at new treatment strategies and advocates for more federal funding of Alzheimer’s research.

Currently, there are five FDA-approved Alzheimer’s drugs that treat the symptoms of Alzheimer’s, but these medications do not treat the underlying causes of Alzheimer’s. In contrast, many of the new drugs in development aim to modify the disease process itself, by impacting one or more of the many wide-ranging brain changes that Alzheimer’s causes. These changes offer potential “targets” for new drugs to stop or slow the progress of the disease.

Many researchers believe successful treatment will eventually involve a “cocktail” of medications aimed at several targets, similar to current state-of-the-art treatments for many cancers and AIDS.

Targets for future drugs

Over the last 30 years, researchers have made remarkable progress in understanding healthy brain function and what goes wrong in Alzheimer’s disease. The following are examples of promising targets for next-generation drug therapies under investigation in current research studies:

Beta-amyloid is the chief component of plaques, one hallmark Alzheimer’s brain abnormality. Scientists now have an understanding of how this protein fragment is clipped from its parent compound amyloid precursor protein (APP) by two enzymes — beta-secretase and gamma-secretase. Researchers are developing medications aimed at virtually every point in amyloid processing. This includes blocking activity of both enzymes; preventing the beta-amyloid fragments from clumping into plaques; and even using antibodies against beta-amyloid to clear it from the brain.

Tau protein is the chief component of tangles, the other hallmark brain abnormality. Researchers are investigating strategies to keep tau molecules from collapsing and twisting into tangles, a process that destroys a vital cell transport system.

Inflammation is another key Alzheimer’s brain abnormality. Scientists have learned a great deal about molecules involved in the body’s overall inflammatory response and are working to better understand specific aspects of inflammation most active in the brain. These insights may point to novel anti-inflammatory treatments for Alzheimer’s disease.

Gauging treatment impact with brain imaging and biomarkers

In addition to investigating experimental drugs, many clinical trials in progress include various brain imaging studies and testing of blood or spinal fluid. Researchers hope these techniques will one day provide methods to diagnose Alzheimer’s disease in its earliest, most treatable stages — possibly even before symptoms appear.

Learning from families with rare Alzheimer-causing genetic changes

Another approach to testing experimental drugs to be given before symptoms appear focuses on individuals with rare genetic mutations that guarantee they’ll eventually develop Alzheimer’s disease. All of these currently known mutations affect beta-amyloid processing or production.

Participate in a clinical trial

If you are interested in participating in a current clinical trial, use Alzheimer’s Association TrialMatch. a free individualized service that matches volunteers with trials based on certain criteria, such as stage of disease, current treatments and location.


Written by admin


Leave a Reply

Your email address will not be published. Required fields are marked *